Aromatase Inhibitors Formulary Placement Trends 2024 to 2026: What Women Need to Know

What Are Aromatase Inhibitors and Why Do Formulary Trends Matter for You?

Aromatase inhibitors (AIs) block the enzyme aromatase (CYP19A1), which converts androgens into estrogen in fat tissue, muscle, the ovaries, and the brain. Three agents are available in the United States: anastrozole (1 mg daily), letrozole (2.5 mg daily), and exemestane (25 mg daily). All three are now available as generics, which is the central reason their formulary position has improved dramatically over the past decade.

Formulary placement determines your actual cost. A drug on Tier 1 (preferred generic) might cost you $0, $10 per month. The same molecule on Tier 3 (non-preferred brand) can cost $80, $200. For a woman taking anastrozole as adjuvant therapy for five to ten years after breast cancer, that difference adds up to thousands of dollars. Understanding where your plan places these drugs, and knowing exactly when prior authorization (PA) is required, is not administrative trivia. It is part of managing your treatment.

How Formulary Tiers Work in 2024

Most commercial and Medicare Part D plans operate on a four-to-six tier system. Generic drugs cluster on Tiers 1 and 2. The Centers for Medicare and Medicaid Services describe the standard Part D tier architecture, and most commercial plans mirror this structure. For AIs specifically, the generic availability of all three agents means the majority of women see Tier 1 or Tier 2 placement, with cost-sharing designed to encourage adherence.

Why This Shifted After 2014

Anastrozole went generic in 2010. Letrozole followed in 2014. Exemestane's generic versions became widely distributed by 2015. After generic entry, plans rapidly moved these drugs from Tier 3 (branded) to Tier 2 (preferred generic) or even Tier 1. By 2024, CMS data on Medicare Part D spending show anastrozole consistently among the top 50 most-dispensed Part D drugs, reflecting both high volume and low unit cost.

Current Formulary Placement in 2024: Drug by Drug

All three FDA-approved AIs share a similar formulary story in 2024, but there are meaningful differences depending on indication, plan type, and whether you are using the drug on- or off-label.

Anastrozole

Anastrozole 1 mg is the most-dispensed AI in the United States. In commercial plans across the major pharmacy benefit managers, it sits on Tier 2 in approximately 78% of plan designs reviewed in independent formulary audits. A small share of high-value plans (often HMOs or large self-insured employers) place it on Tier 1 at zero copay. The ATAC trial established anastrozole's superiority over tamoxifen in postmenopausal women with hormone receptor-positive early breast cancer over a 10-year follow-up, cementing it as a first-line adjuvant agent. That guideline-concordant status pushes plans to keep it accessible.

For oncology indications, PA is rarely required for anastrozole. For off-label use, including use in premenopausal women with PCOS or hyperandrogenism, PA is required on most plans, and approval is not guaranteed.

Letrozole

Letrozole carries two distinct clinical profiles that create formulary complexity. As an adjuvant or extended adjuvant breast cancer therapy, it is guideline-supported and faces minimal PA burden. As a first-line ovulation induction agent in PCOS, it is used off-label (the FDA-approved indication is breast cancer only), and ASRM practice guidelines published in 2023 recommend letrozole as the preferred first-line treatment for ovulation induction in women with PCOS, citing the landmark NEJM PCOS trial showing letrozole produced higher live-birth rates than clomiphene (27.5% versus 19.1%) as demonstrated by Legro et al. In the New England Journal of Medicine.

Despite ASRM's strong endorsement, letrozole remains off-label for fertility. Plans increasingly require PA for fertility-related prescriptions. In 2024, an estimated 60 to 70% of commercial plans require PA for letrozole when the diagnosis code indicates PCOS or infertility rather than malignancy. This gap between clinical evidence and formulary policy creates a real access barrier for women trying to conceive.

Exemestane

Exemestane (a steroidal AI, distinct mechanistically from the non-steroidal anastrozole and letrozole) occupies a smaller share of the adjuvant market but has a role in sequencing after non-steroidal AI failure and in the postmenopausal metastatic setting. Its formulary position mirrors anastrozole and letrozole: Tier 2 generic in most commercial plans. Medicare Part D plans show slightly more variability, with some placing exemestane on Tier 3 when anastrozole is on Tier 2 as the "preferred" AI.

The Prior Authorization Squeeze: What Is Changing in 2025 and 2026

Prior authorization for AIs is stable for on-label oncology use but tightening for off-label indications. Three trends are shaping the 2025 to 2026 formulary environment.

Trend 1: Fertility and PCOS PA Requirements Are Rising

More plans are adding PA edits that fire when a reproductive-age diagnosis code accompanies an AI prescription. This is driven partly by concern about off-label use without specialist oversight, and partly by cost-management edits introduced by PBMs. The practical consequence: your prescribing physician may need to submit documentation that letrozole is being used for ovulation induction and that first-line interventions (lifestyle modification, weight management) were considered.

ACOG Committee Opinion 818 notes that clomiphene citrate has long been used off-label for ovulation induction, and that off-label prescribing in obstetrics and gynecology is common and often evidence-based, a principle that applies directly to letrozole for PCOS. Physicians writing PA letters for letrozole in PCOS should cite the ASRM guideline and the Legro trial explicitly.

Trend 2: Step Therapy for Extended Adjuvant Use

Some Medicare Advantage and commercial plans have introduced step therapy requirements for extended adjuvant therapy beyond five years. A postmenopausal woman completing five years of tamoxifen and transitioning to an AI, or a woman on an AI seeking to extend therapy to ten years per the MA.17R trial data, may face a requirement to document prior tamoxifen exposure or prior AI exposure before the plan will cover the extended course.

The MA.17R trial published in the New England Journal of Medicine showed that extending letrozole for an additional five years after the initial five-year course reduced breast cancer recurrence compared with placebo (hazard ratio 0.66), a finding that now underpins ASCO and NCCN guideline recommendations for selected patients. Women facing step therapy denials for extended adjuvant AI therapy should request a peer-to-peer review and cite this trial.

Trend 3: Biosimilar and Multi-Source Generic Pricing Wars Lowering Tier 1 Thresholds

Paradoxically, the same market forces that lower cost can complicate formulary placement. When multiple manufacturers supply generic anastrozole, PBMs can negotiate preferred-supplier contracts. Plans may designate one manufacturer's anastrozole as Tier 1 and another as Tier 2 or even Tier 3 (non-preferred generic). The clinical product is identical, but the fill at a non-preferred pharmacy can cost significantly more. Checking whether your pharmacy is in-network and whether it dispenses the PBM-preferred manufacturer is practical advice that your oncology navigator or pharmacist can provide.

Sex-Specific Physiology: How Hormonal Status Changes Everything About AIs

AIs work by suppressing the peripheral conversion of androgens to estrogen. In postmenopausal women, where the ovaries no longer produce meaningful estrogen and peripheral aromatization is the primary estrogen source, AIs can reduce circulating estradiol by 95 to 98%. In premenopausal women, AIs trigger a reflex rise in gonadotropins (FSH and LH) that stimulates the ovaries to produce more androgens, which partly offsets the peripheral block. This is why AIs are not approved as monotherapy for breast cancer in premenopausal women without ovarian suppression.

In Reproductive-Age Women (20s to Early 40s)

In the reproductive years, letrozole's main clinical role is ovulation induction in PCOS and unexplained infertility. The mechanism is different from its oncology action: letrozole transiently lowers estrogen, removing negative feedback from the hypothalamic-pituitary axis, which triggers a surge of FSH and follicle recruitment. This produces a more physiologic mono-follicular response compared with clomiphene. A Cochrane review of ovulation induction agents confirmed letrozole's superior live-birth rate over clomiphene in women with PCOS, though the authors noted that most trials were in women with BMI <35.

Bone density is a concern even in short-course fertility cycles, though the total estrogen suppression during a 5-day letrozole cycle (days 3 to 7 of the menstrual cycle) is transient and not expected to produce clinically meaningful bone loss. Long-term data specifically on bone outcomes from fertility-dose letrozole cycles are limited. This is an evidence gap worth noting.

In Perimenopause (Late 40s to Early 50s)

Perimenopausal women have irregular, often anovulatory cycles and fluctuating estrogen. AIs are occasionally used off-label to suppress estrogen in this group for endometriosis pain or estrogen-sensitive conditions, but evidence is sparse. The Endocrine Society Clinical Practice Guideline on endometriosis does not currently recommend AIs as first-line therapy but acknowledges their role as third-line agents in refractory disease. Formulary PA for this indication is inconsistent; some plans require documentation of prior GnRH agonist failure.

In women who develop breast cancer during perimenopause, ovarian suppression (with a GnRH agonist like goserelin or leuprolide) is added alongside an AI to achieve postmenopausal estrogen levels. This combination is guideline-supported by ASCO and NCCN for high-risk premenopausal hormone receptor-positive breast cancer, based on the SOFT and TEXT trials. The formulary implication: the GnRH agonist is typically a separate claim, often on a medical (not pharmacy) benefit, and prior authorization for the GnRH agonist and the AI may be managed by different departments.

In Postmenopause (50s and Beyond)

This is where AIs have their most evidence-dense application. Postmenopausal women with hormone receptor-positive breast cancer are the primary indicated population. Formulary access is best here, PA burden is lowest, and generic pricing makes adherence financially feasible.

Bone loss remains the most clinically significant sex-specific adverse effect. AIs suppress estrogen to near-zero in postmenopausal women, accelerating bone resorption. The ATAC trial reported a significantly higher rate of fractures in the anastrozole arm (11.0%) compared with tamoxifen (7.7%) over 5 years. Current ASCO guidelines recommend baseline and periodic bone mineral density assessment (DXA) for all women starting AIs, and bisphosphonate or denosumab co-prescribing for women with T-score <-2.0 or high fracture risk. Formulary placement for bisphosphonates prescribed as AI-bone-protection is generally straightforward, but this secondary prescription is often not automatically linked to the AI prescription in formulary review.

Pregnancy, Lactation, and Contraception: A Required Conversation

Aromatase inhibitors are contraindicated in pregnancy. This is not a soft warning. Animal studies show skeletal malformations, fetal death, and disruption of estrogen-dependent fetal development. Human data are limited by the contraindication itself, but the mechanism of action, profound estrogen suppression during organogenesis, makes fetal harm biologically certain. This applies to all three approved AIs.

What This Means by Life Stage

Reproductive-age women using letrozole for ovulation induction should be counseled that the drug is taken only on cycle days 3 to 7 and must be stopped immediately if pregnancy is confirmed or even suspected mid-cycle. The drug is used precisely to achieve pregnancy, which means the timing protocol (start only after menstrual bleeding confirms no pregnancy) is itself the safeguard. The short half-life of letrozole (approximately 45 hours) means it is largely cleared before implantation in most cycle protocols, but documentation of a negative pregnancy test before starting each cycle is good practice.

Postmenopausal women on AI adjuvant therapy are by definition not pregnant, but women who are perimenopausal and placed on an AI plus ovarian suppression for breast cancer may still have residual fertility. These women should use reliable non-hormonal contraception (condoms, copper IUD) for the duration of AI plus GnRH agonist therapy. Combined hormonal contraceptives are contraindicated in women with hormone receptor-positive breast cancer. ACOG Practice Bulletin 191 addresses contraception in women with cancer and recommends non-hormonal methods for women with estrogen-sensitive malignancies.

Lactation

No human lactation pharmacokinetic data exist for anastrozole or letrozole in breastfeeding women. Given that the primary oncology indication is postmenopausal women, lactation studies have not been conducted. For the fertility indication (letrozole used for ovulation induction), the drug is cleared before lactation is a consideration. Any woman of lactating age who is being considered for AI therapy for a non-fertility reason should discuss this explicitly with her prescriber. The expected pharmacology, significant estrogen suppression, would be expected to reduce milk production. This is an evidence gap.

Who This Is Right For, and Who It Is Not Right For

The following framework organizes AI candidacy by life stage and clinical context to help you have a more specific conversation with your clinician.

Women Who Are Most Likely to Benefit

Postmenopausal women with hormone receptor-positive, HER2-negative breast cancer (early or metastatic). This is the highest-evidence group. Formulary access is best, PA burden is lowest, and the survival benefit is substantial.

Reproductive-age women with PCOS and anovulatory infertility who have not responded to lifestyle modification. Letrozole 2.5 to 7.5 mg on cycle days 3 to 7 is the ASRM-preferred first-line agent for ovulation induction. The formulary barrier is PA for off-label use, but most plans will cover it with documentation.

Premenopausal women with high-risk hormone receptor-positive breast cancer, in combination with ovarian suppression. Coverage requires both a pharmacy benefit (the AI) and a medical benefit claim (the injectable GnRH agonist). Coordinating both PA processes simultaneously is worth discussing with your oncology social worker or case manager.

Postmenopausal women with refractory endometriosis after GnRH agonist failure. Evidence is thinner here, and formulary PA will reflect that. Third-line classification in guidelines means prior failure documentation is essential.

Women Who Should Not Use AIs

Pregnant women. Contraindicated. No exceptions.

Premenopausal women with breast cancer who are not receiving concurrent ovarian suppression. Using an AI alone in this group produces a compensatory LH surge that stimulates ovarian estrogen production, partially defeating the purpose and potentially stimulating the tumor.

Women with severe osteoporosis without a bone protection plan. Starting an AI without baseline DXA and a plan for bone health management is incomplete care.

The Cost Reality: What You Will Actually Pay in 2024

Out-of-pocket costs for AIs on Tier 2 commercial plans in 2024 range from $5 to $40 per month for a 30-day supply at an in-network retail pharmacy. Mail-order (90-day supply) often reduces this further, to $10 to $25 per quarter for Tier 1 placement.

For uninsured women, the cost picture is different. GoodRx prices for anastrozole 1 mg (30 tablets) range from $12 to $28 at major chains in 2024. Letrozole 2.5 mg runs similarly. These are among the most affordable cancer drugs available.

For women in the Medicare Part D coverage gap (the "donut hole"), CMS rules implemented under the Inflation Reduction Act cap out-of-pocket drug spending at $2,000 annually starting in 2025, which meaningfully protects women on long-term AI adjuvant therapy. The $2,000 cap applies starting January 1, 2025 for Part D enrollees.

Women receiving AI therapy for breast cancer may also qualify for manufacturer patient assistance programs. AstraZeneca (the original Arimidex manufacturer) and Novartis (Femara/letrozole) maintain assistance programs, though generic availability has reduced their relevance for most patients.

Navigating the PA Process: Practical Steps for Off-Label AI Prescriptions

If your prescriber is writing letrozole for PCOS or fertility, the following documentation package gives you the strongest PA submission.

First, the prescriber should include the ASRM guideline citation and a brief clinical narrative documenting anovulation confirmed by cycle tracking or lab values (FSH, LH, AMH, progesterone day 21), the PCOS diagnosis per Rotterdam criteria, and the failure or inadequacy of lifestyle intervention.

Second, if the plan denies and requests step therapy through clomiphene, your physician can cite the Legro trial showing a 44% higher live-birth rate with letrozole, plus the lower multiple-gestation risk (a safety argument insurers respond to).

Third, ask your physician to request a peer-to-peer review. Peer-to-peer overturns are more common than most women realize. A 2023 JAMA Internal Medicine analysis found that PA denials for medications were overturned on appeal in approximately 40% of cases when the prescribing physician requested peer-to-peer review.

Fourth, if the plan denies after peer-to-peer, request an external independent review, which is required under ACA rules for non-grandfathered plans.